CLINICS 2011;66(3):493-499 21. Kraemer KH, Greene MH. Dysplastic nevus syndrome: familial and sporadic precursor of cutaneous melanoma. Dermatol Clin. 1985;3:225- 37, doi: 10.1016/0738-081X(85)90096-3. 22. Celebi JT, Ward KM, Wanner M, Polsky D, Kopf AW. Evaluation of germline CDKN2A, ARF, CDK4, PTEN, and BRAF alterations in atypical mole syndrome. Clin Exp Dermatol. 2005;30:68-70, doi: 10.1111/j.1365- 2230.2004.01656.x. 23. Landman G. Atypical (dysplastic) cell nevus: histopathology and historical aspects. Acta oncol. Bras. 2003;23:514-20. 24. Goldstein AM, Martinez M, Tucker MA, Demenais F. Gene-covariate interaction between dysplastic nevi and the CDKN2A gene in American melanoma-prone families. Cancer Epidemiol Biomarkers Prev. 2000;9:889-94. 25. Chaudru V, Laud K, Avril MF et al. Melanocortin-1 receptor (MC1R) gene variants and dysplastic nevi modify penetrance of CDKN2A mutations in French melanoma-prone pedigrees. Cancer Epidemiol Biomarkers Prev. 2005;14:2384-90, doi: 10.1158/1055-9965.EPI-04-0777. 26. Bevona C, Goggins W, Quinn T, Fullerton J, Tsao H. Cutaneous melanomas associated with nevi. Arch Dermatol. 2003;139:1620-4, doi: 10.1001/archderm.139.12.1620. 27. Halpern AC, Guerry D 4th, Elder DE, Trock B, Synnestvedt M, Humphreys T, . Natural history of dysplastic nevi. J Am Acad Dermatol. 1993;29:51-7, doi: 10.1016/0190-9622(93)70151-I. 28. Kopf AW, Friedman RJ, Rigel DS. Atypical mole syndrome. J Am Acad Dermatol. 1990;22:117-8, doi: 10.1016/S0190-9622(08)80006-0. 29. NIH Consensus conference. Diagnosis and treatment of early melanoma. JAMA. 1992;268:1314-9, doi: 10.1001/jama.268.10.1314. 30. Rigel DS, Rivers JK, Kopf AW, Friedman RJ, Vinokur AF, Heilman ER, et al. Dysplastic nevi: markers for increased risk for melanoma. Cancer. 1989;63:386-9, doi: 10.1002/1097-0142(19890115)63:2,386::AID- CNCR2820630231.3.0.CO;2-6. 31. Lynch HT, Frichot BC III, Lynch JF. Familial atypical multiple mole- melanoma syndrome. J Med Genet. 1978;.15:..352-6, doi: 10.1136/jmg.15. 5.352. 32. Tucker MA, Fraser MC, Goldstein AM, Elder DE, Guerry D 4th, Organic SM, et al. The risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol. 1993; 100: 350-5, doi: 10.1038/jid.1993.62. 33. Terushkin V, Halpern AC. Melanoma Early Detection. Hematol Oncol Clin North Am. 2009;23:481-500, doi: 10.1016/j.hoc.2009.03.001. 34. Kittler H, Pehamberger H, Wolff K, Binder M. Follow-up of melanocytic skin lesions with digital epiluminescence microscopy: patterns of modifications observed in early melanoma, atypical nevi, and common nevi. J Am Acad Dermatol. 2000;43:467-76, doi: 10.1067/mjd.2000.107504. 35. Carli P, de Giorgi V, Chiarugi A et al. Addition of dermoscopy to conventional naked-eye examination in melanoma screening: a rando- mized study. J Am Acad Dermatol. 2004;50:683-9, doi: 10.1016/j.jaad. 2003.09.009. 36. Annessi G, Bono R, Sampogna F, Faraggiana T, Abeni D. Sensitivity, specificity, and diagnostic accuracy of three dermoscopic algorithmic methods in the diagnosis ofdoubtful melanocytic lesions: the importance of light brown structureless areas in differentiating atypical melanocytic nevi from thim melanomas. J Am Acad Dermatol. 2007;56:759-67, doi: 10. 1016/j.jaad.2007.01.014. 37. Malvehy J, Puig S, Braun R, Marghood A, Kopf A. Lesiones Melanoc´ıticas In: Malvehy J, Puig S, Braun R, Marghood A, Kopf A, eds. Manual de Dermatoscop´ıa. Barcelona: BCN Art Directe S.L.; 2006. p45-54. 38. Rezze GG, Soares de Sa´ BC, Neves RI. Dermatoscopia: o me´todo de ana´lise de padro˜ es. An Bras Dermatol. 2006;81:261-8, doi: 10.1590/S0365- 05962006000300009. 39. Soares de Sa´ BC, Rezze GG. Dermatoscopia dos Nevos At´ıpicos. In: Rezze GG, Soares de Sa´ BC, Neves RI, eds. Atlas de Dermatoscopia Aplicada, 1st. ed. Sa˜o Paulo, SP: Lemar-Martinari; 2009. p103-7. 40. Nathansohn N, Orenstein A, Trau H, Liran A, Schachter J. Pigmented lesions clinic for early detection of melanoma: preliminary results. Isr Med Assoc J. 2007;9:708-12. Silva JH et al. 41. Bowling J, Argenziano G, Azenha A, Bandic J, Bergman R, Blum A, et al. Dermoscopy key points: recommendations from the international dermoscopy society. Dermatology. 2007;214:3-5, doi: 10.1159/000096904. 42. Haenssle HA, Vente C, Bertsch HP, Rupprecht R, Abuzahra F, Junghans V, et al. Results of a surveillance programme for patients at high risk of malignant melanoma using digital and conventional dermoscopy. Eur J Cancer Prev. 2004;13:133-8, doi: 10.1097/00008469-200404000- 00007. 43. Lucas CR, Sanders LL, Murray JC, Myers SA, Hall RP, Grichnik JM. Early melanoma detection:nonuniform dermoscopic features ad growth. J Am Acad Dermatol. 2003;48:663-71, doi: 10.1067/mjd.2003.283. 44. Banky JP, Kelly JW, English DR, Yetman JM, Dowling JP. Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients with high risk for melanoma. Arch Dermatol. 2005;141:998-1006, doi: 10.1001/archderm.141.8.998. 45. Menzies SW. Cutaneous melanoma: making a clinical diagnosis, present and future. Dermatol Ther. 2006;19:32-9, doi: 10.1111/j.1529-8019.2005. 00054.x. 46. Menzies SW, Gutenev A, Avramidis M, Batrac A, McCarthy WH. Short- term digital surface microscopic monitoring of atypical or changing melanocytic lesions. Arch Dermatol. 2001;137:1583-9. 47. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol. 2001;19:3635-48. 48. Rigel DS, Friedman RJ, Kopf AW, Weltman R, Prioleau PG, Safai B, et al. Importance of complete cutaneous examination for the detection of malignant melanoma. J Am Acad Dermatol. 1986;14: 857-60, doi: 10. 1016/S0190-9622(86)70100-X. 49. Pehamberger H, Steiner A, Wolff K. In vivo epiluminescence microscopy of pigmented skin lesions: I. pattern analysis of pigmented skin lesions. J Am Acad Dermatol. 1987;17:571-83, doi: 10.1016/S0190-9622(87)70239-4. 50. Steiner A, Pehamberger H, Wolff K. In vivo epiluminescence microscopy of pigmented skin lesions: II. Diagnosis of small pigmented skin lesions and early detection of malignant melanoma. J Am Acad Dermatol. 1987;17:584-91. 51. D Aurea Machado EDB. Histo´ rio e Fundamentos da Dermatoscopia. In: Rezze GG, Soares de Sa´ BC, Neves RI, eds. Atlas de Dermatoscopia Aplicada, 1st. ed. Sa˜o Paulo, SP: Lemar-Martinari; 2009. p17-21. 52. Stratigos AJ, Dover JS, Arndt KA. Laser treatment of pigmented lesions - 2000: how far have we gone? Arch Dermatol. 2000;136: 915-21, doi: 10. 1001/archderm.136.7.915. 53. Rodriguez-Sains RS. Ocular findings in patients with dysplastic nevus syndrome. Ophthalmology. 1986;93:661-5. 54. Vink J, Crijns MB, Mooy CM et al. Ocular melanoma in families with dysplastic nevus syndrome. J Am Acad Dermatol. 1990;23: 858-62, doi: 10.1016/0190-9622(90)70304-Z. 55. Elwood JM, Gallagher RP, Hill GB, Spinelli JJ, Pearson JC, Threlfall W. Pigmentation and skin reaction to sun as risk factors for cutaneous melanoma: Western Canada Melanoma Study. Br Med J. 1984;288:99-102, doi: 10.1136/bmj.288.6411.99. 56. Noz KC, Bauwens M, van Buul PP, Vrolijk H, Schothorst AA, Pavel S, et al. Comet assay demonstrates a higher ultraviolet B sensitivity to DNA damage in dysplastic nevus cells than in common melanocytic nevus cells and foreskin melanocytes. J Invest Dermatol. 1996;106:1198-202, doi: 10.1111/1523-1747.ep12347994. 57. Perera MI, Um KI, Greene MH, Waters HL, Bredberg A, Kraemer KH. Hereditary dysplastic nevus syndrome: lymphoid cell ultraviolet hypermutability in association with increased melanoma susceptibility. Cancer Res. 1986;46:1005-9. 58. Niendorf KB, Tsao H. Cutaneous melanoma: Family screening and genetic testing. Dermatol Ther. 2006; 19: 1-8, doi: 10.1111/j.1529-8019. 2005.00050.x. 59. Pho L, Grossman D, Leachman AS. Melanoma genetics: a review of genetic factor and clinical phenotypes in familial melanoma. Curr Opin Oncol. 2006;18:173-9, doi: 10.1097/01.cco.0000208791.22442.09. 499